Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Nuveen Asset Management LLC

Nuveen Asset Management LLC increased its stake in Royalty Pharma plc (NASDAQ:RPRX) by 0.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 944,601 shares of the biopharmaceutical company’s stock after buying an additional 8,802 shares during the quarter. Nuveen Asset Management LLC owned about 0.16% of Royalty Pharma worth $24,097,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of RPRX. Occudo Quantitative Strategies LP grew its stake in Royalty Pharma by 96.4% during the 4th quarter. Occudo Quantitative Strategies LP now owns 22,512 shares of the biopharmaceutical company’s stock valued at $574,000 after purchasing an additional 11,052 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Royalty Pharma by 25.2% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 66,501 shares of the biopharmaceutical company’s stock valued at $1,696,000 after purchasing an additional 13,376 shares in the last quarter. Ethic Inc. grew its stake in Royalty Pharma by 132.6% during the 4th quarter. Ethic Inc. now owns 20,342 shares of the biopharmaceutical company’s stock valued at $519,000 after purchasing an additional 11,597 shares in the last quarter. D. E. Shaw & Co. Inc. grew its stake in Royalty Pharma by 24.6% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,161,304 shares of the biopharmaceutical company’s stock valued at $29,625,000 after purchasing an additional 228,964 shares in the last quarter. Finally, Deutsche Bank AG grew its stake in Royalty Pharma by 36.2% during the 4th quarter. Deutsche Bank AG now owns 3,189,964 shares of the biopharmaceutical company’s stock valued at $81,376,000 after purchasing an additional 847,704 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on RPRX shares. Morgan Stanley began coverage on Royalty Pharma in a research note on Friday, May 16th. They set an “overweight” rating and a $51.00 price objective for the company. Citigroup reissued a “buy” rating on shares of Royalty Pharma in a report on Friday, March 28th. Finally, Wall Street Zen lowered shares of Royalty Pharma from a “buy” rating to a “hold” rating in a report on Tuesday. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $42.50.

Royalty Pharma Price Performance

Shares of RPRX opened at $32.31 on Friday. The firm has a market cap of $18.63 billion, a price-to-earnings ratio of 22.28, a PEG ratio of 2.31 and a beta of 0.49. The stock has a 50 day moving average of $32.42 and a 200-day moving average of $30.13. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.32.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.99 by $0.07. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. The business had revenue of $839.00 million during the quarter, compared to analyst estimates of $724.69 million. As a group, analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 2.72%. The ex-dividend date of this dividend is Friday, May 16th. Royalty Pharma’s dividend payout ratio (DPR) is presently 47.57%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.